SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stem Cell Research

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Doc Bones11/14/2005 4:21:38 AM
   of 495
 
Cell Therapy Aids In Heart Function After an Attack

REUTERS NEWS SERVICE
November 14, 2005; Page B5

DALLAS -- Heart-attack survivors whose hearts were infused with stem cells from their own bone marrow showed nearly twice the improvement in the organ's pumping ability as patients given a placebo, according to a new study.

The primary goal of the 204-patient study was to show improvement in function of the left ventricle -- the pumping chamber of the heart -- which is considered a good gauge of a patient's prognosis following a heart attack.

Both groups in the study had nearly identical left ventricular function going in, and both showed improvement after four months as expected, researchers said. But patients who received the bone marrow cell infusion saw an improvement in their left ventricular ejection fraction -- a measure of heart efficiency -- on average, of 5.5%. Those getting a placebo saw a 3% improvement. The results were presented at the American Heart Association annual scientific meeting here.

A further analysis of the data found that benefits to heart function seen four months after an attack appeared to be most pronounced in patients with more severe heart attacks that caused greater damage to the muscle, the researchers said.

"The medications and interventional therapies available so far are intended only to limit further damage to the heart," said Andreas Zeiher, professor at J.W. Goethe University in Frankfurt, and a senior author of the study. "In contrast, progenitor cell therapy has the potential not only to limit further damage, but to regenerate heart function," he said.

Progenitor cells are immature cells that can become a variety of specialized cells.

Researchers said the results stood in contrast to "widely mixed results" seen in prior smaller studies of the cell therapy. They were further encouraged by other results, including less heart enlargement seen in the bone-marrow-cell patients, and improved blood flow in the artery where the attack occurred, indicating the possibility that new blood vessels may have been created to nourish the damaged area.

Heart enlargement, which often occurs after an attack as the heart tries to compensate for reduced pumping ability, is a hallmark of a failing heart.

online.wsj.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext